Targeted therapy: Apatinib — new third-line option for refractory gastric or GEJ cancer

@article{Aoyama2016TargetedTA,
  title={Targeted therapy: Apatinib — new third-line option for refractory gastric or GEJ cancer},
  author={Toru Aoyama and Takaki Yoshikawa},
  journal={Nature Reviews Clinical Oncology},
  year={2016},
  volume={13},
  pages={268-270}
}